These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2484694)

  • 1. Molsidomine is a donor of EDRF.
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S139-40. PubMed ID: 2484694
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
    Bult H; Fret HR; Herman AG
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.
    Gerzer R; Drummer C; Karrenbrock B; Heim JM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S115-9. PubMed ID: 2484688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries.
    Kukovetz WR; Holzmann S
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S40-6. PubMed ID: 2484698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of platelet activation by endothelium-derived relaxing factor EDRF/NO and NO releasing dilator substances].
    Bassenge E
    Z Kardiol; 1991; 80 Suppl 5():17-21. PubMed ID: 1776330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of altered nitric oxide synthesis and of exogenous nitric oxide on the proliferation of mesangial cells in culture.
    Sterzel RB; Schoecklmann HO; Mohaupt M; Schulze-Lohoff E
    Exp Nephrol; 1994; 2(2):146. PubMed ID: 7521775
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of SIN-1 on isolated canine basilar arteries.
    Katusic ZS; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S72-5. PubMed ID: 2484704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIN-1 stimulates the production of cyclic GMP but not cyclic AMP in porcine aortic endothelial cells.
    Schini VB; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S91-4. PubMed ID: 2484708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Linsidomine, direct donor of EDRF/NO: a new treatment for unstable angina].
    Delonca J; Giraud T; Lennuyeux E; Charansonney O
    Arch Mal Coeur Vaiss; 1996 Oct; 89 Spec No 5():19-25. PubMed ID: 8952816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrate tolerance is specific for nitric acid esters and its recovery requires an intact protein synthesis.
    Hinz B; Schröder H
    Biochem Biophys Res Commun; 1998 Nov; 252(1):232-5. PubMed ID: 9813175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasodilator effect and tolerance induced by the nitrocompound SIN-1 in rabbit femoral artery.
    Govantes C; Rodríguez-Martínez MA; Marín J
    Methods Find Exp Clin Pharmacol; 1996; 18(6):387-95. PubMed ID: 8892268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-ischemic actions of molsidomine by venous and large coronary dilatation in combination with antiplatelet effects.
    Bassenge E; Mülsch A
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S23-8. PubMed ID: 2484695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of molsidomine and its metabolites on polymorphonuclear cell function and arachidonic acid metabolism.
    Schröder H; Ney P; Woditsch I; Schrör K
    Prog Clin Biol Res; 1989; 301():553-9. PubMed ID: 2552466
    [No Abstract]   [Full Text] [Related]  

  • 14. Relaxations to endothelium-derived relaxing factor and the metabolite of molsidomine, SIN-1, in the aorta and the hindquarters of the rat.
    Van de Voorde J; Claeys M; Leusen I
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S55-61. PubMed ID: 2484700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molsidomine.
    Reden J
    Blood Vessels; 1990; 27(2-5):282-94. PubMed ID: 2242448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate.
    Grosser N; Schröder H
    Biochem Biophys Res Commun; 2000 Jul; 274(1):255-8. PubMed ID: 10903927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of NO from molsidomine (SIN-1) in vitro and its relationship to changes in coronary vessel tone.
    Schrör K; Förster S; Woditsch I; Schröder H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S29-34. PubMed ID: 2484696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade.
    Henry PJ; Horowitz JD; Louis WJ
    J Pharmacol Exp Ther; 1989 Feb; 248(2):762-8. PubMed ID: 2563771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonal changes of guanidine 3', 5'-cyclic monophosphate related to endothelium-derived relaxing factor in dog renal medulla.
    Biondi ML; Bolterman RJ; Romero JC
    Ren Physiol Biochem; 1992; 15(1):16-22. PubMed ID: 1372744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.